TD Cowen analyst Dan Brennan raised the firm’s price target on NeoGenomics (NEO) to $14 from $13 and keeps a Buy rating on the shares. The firm said they reported a modest beat and raise in 1Q including 23% NGS growth. While the beat was driven by ASP upside, given concerns into results about a weather-induced miss, Cowen expectsresults to be well received.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Buy Rating Reaffirmed as Growth and Profitability Improve; $15 Price Target Maintained
- Leerink upgrades NeoGenomics to Outperform, raises target to $25
- NeoGenomics upgraded to Buy from Hold at Benchmark
- NeoGenomics upgraded to Outperform from Market Perform at Leerink
- NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c